Skip to main content
Figure 2 | Journal of Translational Medicine

Figure 2

From: Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study

Figure 2

Immunohistochemical studies on key molecules in tumor growth and metastases. C1, D1 &P1: the cytoplasmic expression of Cat B in 33 tumors was similar among the 3 groups. C2, D2 &P2: The Ki-67 positive rate in the Control group (C2, 77.1%) was significantly higher than those in the DOX group (D2, 72.3%) and the PDOX group (P2, 61.6%) (Control vs DOX: P < 0.05, Control vs PDOX: P < 0.05, DOX vs PDOX: P < 0.05). C3, D3 &P3: The CD34 positive micro-vessels density was similar among the 3 groups. C4, D4 &P4: The rates of VEGF positive cells were similar among 3 groups. C5, D5 &P5: The positive expression of E-Cadherin was similar among the 3 groups. C6, D6 &P6: The D2-40 positive lymph vessels were also similar among the 3 groups. C: Control; D: DOX; P: PDOX. 400×, scale bar = 20 μm.

Back to article page